Tandem Diabetes Care Snags $52M Financing for Insulin Pumps
Summary
Tandem didn’t respond to a request for comment Saturday, so if I hear anything from them I’ll be sure to update this story.The company says it is “deep in product development” of new kinds of insulin pumps that will enable diabetics to remain active.This is a big business opportunity as the incidence of diabetes, a lifelong condition in which people struggle to maintain normal blood sugar levels, keeps on climbing.“Experience also comes from our on-staff insulin pump users and the former executives of leading life science companies who are committed to creating and offering products that provide people with freedom, style, and peace of mind.Besides Blickenstaff, Tandem’s board includes Dick Allen, a prominent startup investor; Greene, the co-founder of Amylin; John Livingston, a former executive with MiniMed; Tandem founder Paul DiPerna; Jesse Treu of Domain Associates; Ned Brown of TPG Biotech; Doug Roeder of Delphi Ventures; and Ed Cahill of HLM Venture Parnters.
Classifications
AskAI Classifications
LabelsLinked Companies
